Amgen secures $70m in biosimilar clash with Hospira
26-09-2017
Federal Circuit rejects Amgen biosimilar discovery request
11-08-2017
02-10-2017
AndreyPopov / iStockphoto.com
Hospira has appealed against a verdict which saw Amgen secure $70 million in damages over a biosimilar dispute between the two companies.
Start a subscription today to access the LSIPR website.
To access the full archive, digital magazines and special reports you will need to take out a paid subscription.
If you have already subscribed please login.
If you have any technical issues please email tech support.
For access to the complete website, archive, and to receive print publications, choose '12 MONTH SUBSCRIPTION'. For a free, two-week trial with full access, select ‘TWO WEEK FREE TRIAL’.
Amgen, Hospira, patent, patent infringement, biosimilar, Biologics Price Competition and Innovation Act, anaemia